Diabetes is bleeding Indians dry

NEW DELHI: The mounting prevalence of diabetes with complications like obesity, blood pressure and cholesterol among Indians is leading to spiralling cost of treatment and a massive burden on out-of pocket expenditure.

The total healthcare expenditure on diabetes in India was estimated at $31 billion in 2017 with 86% of rural and 82% of urban populations in India having to bear the costs of disease management through out-of pocket expenses, a new study published in Lancet shows.

According to the study, the expenditure of an average Indian patient with type 2 diabetes was estimated to be $95 per year. The costs of care include direct, indirect, and intangible costs.

Diabetes is bleeding Indians dry
Though use of low cost drugs and insulin have helped keep the expenditure on diabetes management under check, the enormous cost is driven by increasing prevalence of diabetes, mainly with complications. Researchers also observed that gradually use of (and thus expenditure on) newer oral drugs and insulins are increasing in India.

Diabetes prevalence has increased by 64% across India over the quarter-century. According to International Diabetes Federation, India’s diabetes population totalled 74 million in 2017 and it is estimated to reach 134.3 million people by 2045.

“When complications occur, these costs increase exponentially, particularly when insulin is initiated or admission to hospital or surgery are required…” says Dr Anoop Misra, chairman, Fortis C-Doc. He is one of the authors of the study. Other researchers include Nikhil Tandon from AIIMS and Andrew P Hills from University of Tasmania. The study linked higher spend on the disease management with higher income. In India, infections contribute to 41% of deaths among patients with diabetes.

ETPrime

Polio virus to India: The news of my death has been grossly exaggerated. Hello again!
NewsletterA A

inShare

Subscribe ETHealthworld Newsletter
150000+ Industry Leaders already read it everyday

Your Email

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Diabetic drug metformin found to act on brain

    Diabetic drug metformin found to act on brain

    Hetero debuts semaglutide generic in emerging markets

    Hetero debuts semaglutide generic in emerging markets

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework